All‐cause mortality – deaths · adults with or without existing CVD
High showed no clear difference in all‐cause mortality – deaths compared with low alpha‐linolenic acid omega‐3 fats (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality within · Individuals with peripheral arterial disease
The intervention showed no clear difference in mortality within (high certainty).
1 finding from 1 review
Long‐term all‐cause mortality · people with low‐risk acute pulmonary embolism
Outpatient showed no clear difference in long‐term all‐cause mortality compared with inpatient treatment (low certainty).
1 finding from 1 review
Mortality related to COVID‐19 · people hospitalised with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term all‐cause mortality · people with low‐risk acute pulmonary embolism
2 findings from 1 review
Maternal mortality ‐ not reported · women with primary postpartum haemorrhage following vaginal or caesarean birth
Standard care plus IV tranexamic acid showed no clear difference in maternal mortality (all causes) compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Mortality: all cancers · adults (aged at least 18 years)
Highest showed no clear difference in any cancer mortality (8 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.99 [0.91, 1.07]
504366 participants
Low
Coronary heart disease mortality – CHD deaths · people with or without existing cardiovascular disease, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in coronary heart disease mortality compared with lower PUFA (low certainty).
1 finding from 1 review
Cardiovascular mortality · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Cardiovascular disease mortality: RR 0.55 (95% CI 0.36 to 0.85), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
U5 mortality rate · children U5
1 finding from 1 review
1.16 [0.99, 1.36]
4729 participants
Very low
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
All‐cause mortality ‐ not reported · adults undergoing intra‐ and transperitoneal laparoscopic procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review
Maternal mortality due to bleeding · women with primary postpartum haemorrhage following vaginal or caesarean birth
Standard care plus IV tranexamic acid showed no clear difference in maternal mortality due to bleeding compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Mortality before hospital discharge · ventilated preterm infants with failure of initial non‐invasive respiratory support
nHFV showed no clear difference in mortality before hospital discharge compared with nIPPV following failure of initial non‐invasive respiratory support (low certainty).
1 finding from 1 review
Neonatal mortality · neonates with sepsis
Comparison 1: community‐based antibiotic delivery may leads to lower neonatal mortality compared with standard care (low certainty).
1 finding from 1 review
Neonatal mortality · neonates with possible serious bacterial infection
Comparison 2: any simplified antibiotic regimen showed no clear difference in neonatal mortality compared with the standard antibiotic regimen (7 days injectable benzylpenicillin… (moderate certainty).
1 finding from 1 review
Neonatal mortality · neonates with possible serious bacterial infection
Comparison 2: 7 days oral amoxicillin + injectable gentamicin showed no clear difference in neonatal mortality compared with 7 days injectable benzylpenicillin + injectable gentamicin (moderate certainty).
1 finding from 1 review
Neonatal mortality · neonates with fast breathing alone
Comparison 2: 7 days oral amoxicillin showed no clear difference in neonatal mortality compared with 7 days injectable benzylpenicillin + injectable gentamicin (low certainty).
1 finding from 1 review